Isaura Santos,  —

Catabasis Pharmaceuticals, a company focused on clinical-stage drug development that is supported by a pharmacology technology platform pathway, recently announced that Joanne Donovan, Chief Medical Officer, was invited by Parent Project Muscular Dystrophy (PPMD) to present the latest updates on the upcoming MoveDMD trial. MoveDMD is a Phase ½ clinical trial for …

La Jolla Pharmaceutical Company, a drug development company working on therapies that address life-threatening diseases such as Duchenne muscular dystrophy, recently announced it has entered into an exclusive agreement to acquire the Indiana University Research and Technology Center’s (IURTC) intellectual property rights that cover the derivatives of their next-generation experimental…

In 2005, quarterback Vince Young led his teammates from the University of Texas to a coveted national title while the Revell family back in Austin was just discovering that their son suffered from Duchenne Muscular Dystrophy and would be confined to a wheelchair by the time he was in college. The Revell family’s story…

On May 2, 2015 Bill and Kim Procko will be hosting a skateboarding competition “Carve to CureDuchenne,” which is intended to benefit the nonprofit CureDuchenne organization that funds research projects hoping to find a cure for Duchenne muscular dystrophy and raises awareness about the disease. The fundraising event will take place at…

Toronto will come together on Saturday, May 2nd, to make muscles move against muscular dystrophy. Thousands of people suffering with any kind of neuromuscular disorder in Canada will be supported by the community at the annual Toronto Walk for Muscular Dystrophy. Mayyan Ziv, who is the 2015 Toronto Walk Ambassador, strongly believes in the…

GlobalData recently reported that the global treatment market for Duchenne Muscular Dystrophy will expand in value at a staggering Compound Annual Growth Rate (CAGR) of 160.5%, from about $8.2 million in 2014 to $990 million by 2019. In the latest report, OpportunityAnalyzer: Duchenne Muscular Dystrophy – Opportunity and Market Analysis…

Santhera Pharmaceuticals recently announced it received Fast Track designation from the United Stated Food and Drug Administration (FDA)  for its Raxone®/Catena® (idebenone) to address treatment for Duchenne Muscular Dystrophy (DMD). Through the FDA’s Fast Track program, both the development and review of the drug are facilitated, since the has the potential to treat a severe condition, fill unmet medical…

BioBlast Pharma Ltd., a clinical-stage biotechnology firm focused on orphan disease treatment solutions, recently announced that its intravenous (IV) solution Cabaletta received Fast Track designation from the United States Food and Drug Administration (FDA) to address Oculopharyngeal Muscular Dystrophy (OPMD) patients. Cabaletta is being advanced to address treatment to OPMD, which is an uncommon…

Starting April 1, the public can begin showing their support for Muscular Dystrophy Canada by giving a donation at any of the Canada-based LCBO stores; there are more than 650 throughout Ontario alone. Until April 25, 2015, donation boxes will be displayed at checkout counters. The funds raised from the LCBO Provincial Donation…

Newport Beach-based charity Coalition Duchenne recently launched an interview series titled “Making a Difference in Duchenne” through its Youtube channel featuring those who are making a substantial difference in Duchenne muscular dystrophy care, research, education and awareness. Dr. Eduardo Marbán, who is the director of the Cedars-Sinai Heart Institute in Los Angeles, is the…